<DOC>
	<DOC>NCT00004578</DOC>
	<brief_summary>To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.</brief_summary>
	<brief_title>ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Na√Øve HIV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria HIV1 positive antiretroviraladult males nonpregnant nonlactating females at least 18years old with plasma HIV1 RNA &gt; 5000 copies/mL, who were not acutely ill Exclusion Criteria History of: prior antiretroviral therapy significant drug hypersensitivity psychiatric illness that precludes compliance an active substance abuser positive test results for drug abuse abnormal lab test results (hemoglobin, absolute neutrophil count, platelet count, SGPT/AST or SGPT/ALT, creatinine, fasting triglycerides, significant abnormal ECG results pregnancy or lactating female received another investigational drug within 28 days of study initiation unlikely to comply or unsuitable candidate in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>